Trial intelligence / Profile preview

BFF: Bromocriptine for Fever in Acute Neurologic Injury

NCT03496545Phase 2

Key facts

Status: Completed
Start: Nov 2018
Primary completion: Nov 2019
Countries: 1
Sponsor: University of California, San Francisco
Modality: Orthosteric Ligands

Drugs: bromocriptine
Conditions: fever

Overview

Phase 2, randomised, open-label trial of bromocriptine in fever (2 arms), sponsored by University of California, San Francisco. Primary endpoint: Temperature Burden at 48 hours. Started Nov 2018; status: completed.

Design

2 arms

Study design: RandomizedOpen-label

Acetaminophen
Acetaminophen 650mg q4h
Bromocriptine + Acetaminophen
Bromocriptine 5mg q4h + Acetaminophen 650mg q4h

Who it enrols

Adult patients admitted to the ICU with acute neurologic injury (SAH, ICH, TBI, SDH, ischemic stroke) and fever >= 38.3 C. Excludes patients with acute liver failure, severe cardiovascular disease, or those receiving therapeutic hypothermia.

Endpoints

Primary

Temperature Burden48 hours

Secondary

Incidence of Adverse Events48 hours
Total Time That Temperature is >= 38.3ºC48 hours
Total Time to First Temperature < 37.5ºC48 hours

Beyond the preview

Go deeper on NCT03496545.

Full results, competitive context and analysis are in the Gosset platform.

Full results & analysis

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT03496545.